Drug Search Results
More Filters [+]

Sifalimumab

Alternative Names: sifalimumab, medi-545
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: IFNA Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sifalimumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lupus Erythematosus, Systemic|Myositis

Phase 1: Lupus Erythematosus, Systemic|Polymyositis|Dermatomyositis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MI-CP212

P2

Completed

Myositis|Lupus Erythematosus, Systemic

2015-03-01

2010-024069-30

P2

Completed

Lupus Erythematosus, Systemic

2014-04-17

CD-IA-MEDI-545-1067

P2

Completed

Lupus Erythematosus, Systemic

2013-11-14

D2800C00001

P2

Completed

Lupus Erythematosus, Systemic

2012-11-07

Recent News Events